{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:08Z","timestamp":1790965088626,"version":"4.1.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20784"],"award-info":[{"award-number":["U24A20784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473812"],"award-info":[{"award-number":["82473812"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["LJ232410163056"],"award-info":[{"award-number":["LJ232410163056"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008021","name":"Fujian University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["XJB2022008"],"award-info":[{"award-number":["XJB2022008"]}],"id":[{"id":"10.13039\/501100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008021","name":"Fujian University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["X2023001"],"award-info":[{"award-number":["X2023001"]}],"id":[{"id":"10.13039\/501100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115555","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:46:06Z","timestamp":1758087966000},"page":"115555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors"],"prefix":"10.1016","volume":"166","author":[{"given":"Hongwei","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2025.115555_bb0005","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/cmi.2014.104","article-title":"PD-1 induction through TCR activation is partially regulated by endogenous TGF-\u03b2","volume":"12","author":"Rekik","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115555_bb0010","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.18632\/oncotarget.23683","article-title":"Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma","volume":"9","author":"Nukui","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to Cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0025","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.115555_bb0030","article-title":"Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092116","article-title":"Inflammatory cytokine: an attractive target for Cancer treatment","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hep.28874","article-title":"IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice","volume":"65","author":"Bergmann","year":"2017","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.intimp.2025.115555_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133288","article-title":"Sustaining the activation of EGFR signal by inflammatory cytokine IL17A prompts cell proliferation and EGFR-TKI resistance in lung Cancer","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.intimp.2025.115555_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122932","article-title":"TGF Beta induces vitamin D receptor and modulates mitochondrial activity of human pancreatic Cancer cells","volume":"13","author":"Fiz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0055","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1186\/s12885-019-6321-x","article-title":"CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress","volume":"19","author":"Shi","year":"2019","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0060","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115555_bb0065","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41591-019-0441-3","article-title":"IFN-\u03b3-independent immune markers of mycobacterium tuberculosis exposure","volume":"25","author":"Lu","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0075","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"7693","key":"10.1016\/j.intimp.2025.115555_bb0080","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2025.115555_bb0085","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-\u03b1 directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J. Immunol."},{"issue":"1\u20134","key":"10.1016\/j.intimp.2025.115555_bb0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbrc.2018.11.035","article-title":"Interferon-\u03b2 signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells","volume":"507","author":"Morimoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2025.115555_bb0095","article-title":"A small molecule antagonist of PD-1\/PD-L1 interactions acts as an immune checkpoint inhibitor for NSCLC and melanoma immunotherapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115555_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004032","article-title":"In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies","volume":"10","author":"Ieran\u00f2","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2025.115555_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110331","article-title":"PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes","volume":"38","author":"Nagasaki","year":"2022","journal-title":"Cell Rep."},{"issue":"7528","key":"10.1016\/j.intimp.2025.115555_bb0110","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2025.115555_bb0115","article-title":"Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma","volume":"2","author":"Liu","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0125","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2025.115555_bb0130","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2025.115555_bb0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"20","key":"10.1016\/j.intimp.2025.115555_bb0145","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.intimp.2025.115555_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123550","article-title":"Understanding Inflammasomes and PD-1\/PD-L1 crosstalk to improve Cancer treatment efficiency","volume":"12","author":"Perrichet","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0160","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.intimp.2025.115555_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122533","article-title":"MDSC-targeting gold nanoparticles enhance PD-1 tumor immunotherapy by inhibiting NLRP3 inflammasomes","volume":"307","author":"Zhu","year":"2024","journal-title":"Biomaterials"},{"issue":"672","key":"10.1016\/j.intimp.2025.115555_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq7019","article-title":"Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy","volume":"14","author":"Theivanthiran","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/cells12020294","article-title":"Dexamethasone and OLT1177 cooperate in the reduction of melanoma growth by inhibiting STAT3 functions","volume":"12","author":"Dinarello","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0180","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200962","article-title":"AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma","volume":"218","author":"Fukuda","year":"2021","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115555_bb0185","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2025.115555_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112615","article-title":"Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications","volume":"28","author":"Zhang","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2025.115555_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1393799","article-title":"SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation","volume":"15","author":"Morelli","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115555_bb0200","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115555_bb0205","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jtho.2017.04.017","article-title":"Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade","volume":"12","author":"Akbay","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2025.115555_bb0210","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0215","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5684","article-title":"Drug resistance and tumor immune microenvironment: an overview of current understandings (review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"12","key":"10.1016\/j.intimp.2025.115555_bb0225","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/ni.3868","article-title":"Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor","volume":"18","author":"Maj","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115555_bb0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41413-017-0005-4","article-title":"Transforming growth factor-\u03b2 in stem cells and tissue homeostasis","volume":"6","author":"Xu","year":"2018","journal-title":"Bone Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0235","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cytogfr.2009.07.002","article-title":"TGF-beta3 and cancer: a review","volume":"20","author":"Laverty","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"issue":"5","key":"10.1016\/j.intimp.2025.115555_bb0240","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1308616","article-title":"Blockade of only TGF-\u03b2 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy","volume":"6","author":"Terabe","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0245","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0250","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s10528-023-10591-7","article-title":"A novel TGF-\u03b2-related signature for predicting prognosis, tumor microenvironment, and therapeutic response in colorectal Cancer","volume":"62","author":"Tao","year":"2024","journal-title":"Biochem. Genet."},{"issue":"12","key":"10.1016\/j.intimp.2025.115555_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2025.115555_bb0260","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/ijc.31730","article-title":"Dual TGF-\u03b2 and PD-1 blockade synergistically enhances MAGE-A3-specific CD8(+) T cell response in esophageal squamous cell carcinoma","volume":"143","author":"Chen","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0265","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1038\/s41467-021-25322-y","article-title":"Integrin-\u03b1(V)-mediated activation of TGF-\u03b2 regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade","volume":"12","author":"Malenica","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76130-1","article-title":"Regulatory (FoxP3(+)) T cells and TGF-\u03b2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Koh","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0275","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2104426","article-title":"Enriched circulating and tumor-resident TGF-\u03b2(+) regulatory B cells in patients with melanoma promote FOXP3(+) Tregs","volume":"11","author":"Harris","year":"2022","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0280","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cbin.11524","article-title":"KRAS G12V mutation upregulates PD-L1 expression via TGF-\u03b2\/EMT signaling pathway in human non-small-cell lung cancer","volume":"45","author":"Pan","year":"2021","journal-title":"Cell Biol. Int."},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0285","first-page":"2938","article-title":"Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-\u03b2 signaling mediated downregulation of PD-L1","volume":"13","author":"MacDonald","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004122","article-title":"Colocalized targeting of TGF-\u03b2 and PD-L1 by bintrafusp alfa elicits distinct antitumor responses","volume":"10","author":"Lan","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0295","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-\u03b2 signaling in Cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115555_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113352","article-title":"HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation","volume":"42","author":"Zhang","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0305","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.celrep.2016.03.006","article-title":"Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression","volume":"15","author":"Katlinskaya","year":"2016","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0315","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","article-title":"Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment","volume":"31","author":"Katlinski","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"7528","key":"10.1016\/j.intimp.2025.115555_bb0325","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.intimp.2025.115555_bb0330","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-20-2564","article-title":"Type I IFN activating type I dendritic cells for antitumor immunity","volume":"27","author":"Liang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2025.115555_bb0335","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0345","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2008111","article-title":"Improving cancer immunotherapy by targeting IL-1","volume":"10","author":"Xiao","year":"2021","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.intimp.2025.115555_bb0350","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/hep.32062","article-title":"IL-1\u03b2-induced elevation of solute carrier family 7 member 11 promotes hepatocellular carcinoma metastasis through up-regulating programmed death ligand 1 and Colony-stimulating factor 1","volume":"74","author":"He","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0355","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12916-023-02866-y","article-title":"Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability","volume":"21","author":"Wu","year":"2023","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020433","article-title":"The IL-1 antagonist Anakinra attenuates glioblastoma aggressiveness by dampening tumor-associated inflammation","volume":"12","author":"H\u00fcbner","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0365","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2022.01.004","article-title":"Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer","volume":"40","author":"Nicolas","year":"2022","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0370","article-title":"IL-37: an anti-inflammatory cytokine with antitumor functions","volume":"2","author":"Mei","year":"2019","journal-title":"Cancer Rep. (Hoboken)"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0375","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13309","article-title":"Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds","volume":"20","author":"Hamilton","year":"2021","journal-title":"Aging Cell"},{"issue":"6","key":"10.1016\/j.intimp.2025.115555_bb0380","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.smim.2013.10.014","article-title":"Interleukin-18, more than a Th1 cytokine","volume":"25","author":"Novick","year":"2013","journal-title":"Semin. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2025.115555_bb0385","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"IL-18 induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0390","first-page":"2396","article-title":"IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia","volume":"108","author":"Fiordi","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0395","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12916-023-03026-y","article-title":"Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8(+) T cells to demote the antitumor immunity","volume":"21","author":"Zhang","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2025.115555_bb0400","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2019.03.014","article-title":"Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling","volume":"131","author":"Rice","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2025.115555_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.109925","article-title":"Tumor cell-derived LC3B(+)extracellular vesicles mediate the crosstalk between tumor microenvironment and immunotherapy efficacy in hepatocellular carcinoma via the HSP90\u03b1-IL-6\/IL-8 signaling axis","volume":"261","author":"Chen","year":"2024","journal-title":"Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115555_bb0410","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ijc.33873","article-title":"The effects of TNF-\u03b1\/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer","volume":"150","author":"Qu","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115555_bb0415","first-page":"1185","article-title":"TNF-\u03b1-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer","volume":"2","author":"Tu","year":"2021","journal-title":"Nat. Can."},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0420","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.32738","article-title":"AIF1 + CSF1R + MSCs, induced by TNF-\u03b1, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis","volume":"78","author":"Zong","year":"2023","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.intimp.2025.115555_bb0425","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153242","article-title":"Targeting TNF-\u03b1-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling","volume":"7","author":"Dixit","year":"2022","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0430","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1","volume":"35","author":"Wu","year":"2023","journal-title":"Cell Metab."},{"issue":"11","key":"10.1016\/j.intimp.2025.115555_bb0435","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200434RR","article-title":"TNF-\u03b1-dependent lung inflammation upregulates PD-L1 in monocyte-derived macrophages to contribute to lung tumorigenesis","volume":"36","author":"Wen","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2025.115555_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216642","article-title":"Inhibition of ATM promotes PD-L1 expression by activating JNK\/c-Jun\/TNF-\u03b1 signaling axis in triple-negative breast cancer","volume":"586","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2025.115555_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733136","article-title":"PD-1 blockade on tumor microenvironment-resident ILC2s promotes TNF-\u03b1 production and restricts progression of metastatic melanoma","volume":"12","author":"Howard","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115555_bb0450","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fonc.2016.00050","article-title":"Enrichment of inflammatory IL-17 and TNF-\u03b1 secreting CD4(+) T cells within colorectal tumors despite the presence of elevated CD39(+) T regulatory cells and increased expression of the immune checkpoint molecule, PD-1","volume":"6","author":"Dunne","year":"2016","journal-title":"Front. Oncol."},{"issue":"7756","key":"10.1016\/j.intimp.2025.115555_bb0455","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006616","article-title":"Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer","volume":"12","author":"Gao","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2025.115555_bb0465","article-title":"The prognostic implications and tumor-suppressive functions of CYR61 in estrogen receptor-positive breast cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0470","first-page":"839","article-title":"Depletion of CCN1\/CYR61 reduces triple-negative\/basal-like breast cancer aggressiveness","volume":"12","author":"Espinoza","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115555_bb0475","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/aja.2011.149","article-title":"Cyr61 is a potential prognostic marker for prostate cancer","volume":"14","author":"Terada","year":"2012","journal-title":"Asian J. Androl."},{"issue":"11","key":"10.1016\/j.intimp.2025.115555_bb0480","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/1878-0261.13099","article-title":"Blood-based detection of lung cancer using cysteine-rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study","volume":"15","author":"A\u010dkar","year":"2021","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0485","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjc.6605129","article-title":"Serum amyloid a (SAA): a novel biomarker for uterine serous papillary cancer","volume":"101","author":"Cocco","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0490","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41467-024-46118-w","article-title":"Serum amyloid a promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma","volume":"15","author":"He","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2025.115555_bb0495","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0500","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/1346-8138.14041","article-title":"Synergistic effects of interferon-beta and nivolumab in oral mucosal melanoma","volume":"45","author":"Fusumae","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2025.115555_bb0505","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1249330","article-title":"Combining PD-1\/PD-L1 blockade with type I interferon in cancer therapy","volume":"14","author":"Razaghi","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115555_bb0510","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/0008-5472.CAN-23-2049","article-title":"RNA methyltransferase FTSJ3 regulates the type I interferon pathway to promote hepatocellular carcinoma immune evasion","volume":"84","author":"Zhuang","year":"2024","journal-title":"Cancer Res."},{"issue":"6702","key":"10.1016\/j.intimp.2025.115555_bb0515","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0520","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41401-024-01381-x","article-title":"INHBA promotes tumor growth and induces resistance to PD-L1 blockade by suppressing IFN-\u03b3 signaling","volume":"46","author":"Li","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"issue":"16","key":"10.1016\/j.intimp.2025.115555_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70087","article-title":"Efficacy and safety of PD-1 monoclonal antibody combined with interferon-alpha 1b and anlotinib hydrochloride as the second-line therapy in patients with unresectable advanced melanoma: a retrospective study","volume":"13","author":"Zhao","year":"2024","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0530","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0535","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1078-0432.CCR-20-1610","article-title":"Blocking IL1 Beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses","volume":"27","author":"Aggen","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"7930","key":"10.1016\/j.intimp.2025.115555_bb0540","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0545","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2241710","article-title":"Effective intravenous delivery of adenovirus armed with TNF\u03b1 and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer","volume":"12","author":"Kudling","year":"2023","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.intimp.2025.115555_bb0550","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156628","article-title":"A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells","volume":"132","author":"Holcomb","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0555","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/2326-6066.CIR-22-0304","article-title":"NL-201 upregulates MHC-I expression and Intratumoral T-cell receptor diversity, and demonstrates robust antitumor activity as monotherapy and in combination with PD-1 blockade","volume":"11","author":"Mortales","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115555_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101325","article-title":"Immune regulation and cytotoxic T cell activation of IL-10 agonists - preclinical and clinical experience","volume":"44","author":"Oft","year":"2019","journal-title":"Semin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115555_bb0565","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/2326-6066.CIR-22-0699","article-title":"Combinatorial immunotherapy with agonistic CD40 activates dendritic cells to express IL12 and overcomes PD-1 resistance","volume":"11","author":"Krykbaeva","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2025.115555_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115790","article-title":"Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model","volume":"173","author":"Park","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"19","key":"10.1016\/j.intimp.2025.115555_bb0575","doi-asserted-by":"crossref","first-page":"14803","DOI":"10.18632\/oncotarget.22976","article-title":"Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1\/PD-L1 pathway","volume":"9","author":"Zhao","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2025.115555_bb0580","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3389\/fimmu.2020.00832","article-title":"Engineered IL-21 cytokine Muteins fused to anti-PD-1 antibodies can improve CD8+ T cell function and anti-tumor immunity","volume":"11","author":"Shen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115555_bb0585","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3958069","article-title":"Dual roles of IL-27 in Cancer biology and immunotherapy","volume":"2017","author":"Fabbi","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2025.115555_bb0590","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fcell.2020.00210","article-title":"Intra-Tumoral delivery of IL-27 using adeno-associated virus stimulates anti-tumor immunity and enhances the efficacy of immunotherapy","volume":"8","author":"Hu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2025.115555_bb0595","article-title":"PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner","volume":"28","author":"He","year":"2021","journal-title":"Cancer Treat Res. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0600","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00262-023-03580-7","article-title":"Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity","volume":"73","author":"Yue","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2025.115555_bb0605","article-title":"Local release of TGF-\u03b2 inhibitor modulates tumor-associated neutrophils and enhances pancreatic Cancer response to combined irreversible electroporation and immunotherapy","volume":"9","author":"Peng","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0610","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1811605","article-title":"Pan-TGF\u03b2 inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade","volume":"9","author":"Greco","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0615","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0620","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cac2.12244","article-title":"Anti-PD-L1\/TGF-\u03b2R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1\/PD-L1 inhibitors in lung cancer","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0625","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1080\/21655979.2022.2051688","article-title":"Suppression of the transforming growth factor-\u03b2 signaling pathway produces a synergistic effect of combination therapy with programmed death receptor 1 blockade and radiofrequency ablation against hepatic carcinoma in mice","volume":"13","author":"Fan","year":"2022","journal-title":"Bioengineered"},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0630","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-19-0267","article-title":"PD-1 blockade reinvigorates bone marrow CD8(+) T cells from patients with multiple myeloma in the presence of TGF\u03b2 inhibitors","volume":"26","author":"Kwon","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.intimp.2025.115555_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215220","article-title":"Next-generation antisense oligonucleotide of TGF-\u03b22 enhances T cell-mediated anticancer efficacy of anti-PD-1 therapy in a humanized mouse model of immune-excluded melanoma","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.intimp.2025.115555_bb0640","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41419-023-06198-w","article-title":"SAA suppresses \u03b1-PD-1 induced anti-tumor immunity by driving T(H)2 polarization in lung adenocarcinoma","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0645","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose Apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung Cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.115555_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112437","article-title":"Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy","volume":"42","author":"Luo","year":"2023","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.intimp.2025.115555_bb0655","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.21037\/tcr-23-2328","article-title":"Low-dose apatinib optimizes the vascular normalization and enhances the antitumor effect of PD-1 inhibitor in gastric cancer","volume":"13","author":"Tao","year":"2024","journal-title":"Transl. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115555_bb0660","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157347","article-title":"Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma","volume":"8","author":"Tran","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2025.115555_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109746","article-title":"Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model","volume":"125","author":"Wu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115555_bb0670","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3389\/fphar.2019.01184","article-title":"Safety and efficacy of therapeutic Cancer vaccines alone or in combination with immune checkpoint inhibitors in Cancer treatment","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115555_bb0675","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.115555_bb0680","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2016.08.065","article-title":"Timeline: Cellular Oxygen Sensing","volume":"167","author":"Szewczak","year":"2016","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.intimp.2025.115555_bb0685","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1007\/s00784-023-05139-3","article-title":"Are comorbidities associated with the cytokine\/chemokine profile of persistent apical periodontitis?","volume":"27","author":"Agger","year":"2023","journal-title":"Clin. Oral Investig."},{"key":"10.1016\/j.intimp.2025.115555_bb0690","article-title":"Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor\/ligand targeted cancer immunotherapy","volume":"15","author":"Gao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115555_bb0695","doi-asserted-by":"crossref","first-page":"1218082","DOI":"10.3389\/fimmu.2023.1218082","article-title":"Engineering cytokines for cancer immunotherapy: a systematic review","volume":"14","author":"Fu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115555_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/frhs.2023.1034256","article-title":"Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: a systematic review and methodological quality assessment","volume":"3","author":"Zaim","year":"2023","journal-title":"Front Health Serv"},{"issue":"24","key":"10.1016\/j.intimp.2025.115555_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417325","article-title":"The Nexus of inflammation-induced epithelial-mesenchymal transition and lung Cancer progression: a roadmap to Pentacyclic triterpenoid-based therapies","volume":"24","author":"Odarenko","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115555_bb0710","article-title":"Advancing non-small cell lung cancer treatment: the power of combination immunotherapies","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115555_bb0715","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1172\/JCI120775","article-title":"Emerging strategies for combination checkpoint modulators in cancer immunotherapy","volume":"128","author":"Popovic","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.intimp.2025.115555_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041143","article-title":"Cancer resistance to immunotherapy: comprehensive insights with future perspectives","volume":"15","author":"Said","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925015462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925015462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:59:36Z","timestamp":1778619576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925015462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":144,"alternative-id":["S1567576925015462"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115555","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115555"}}